Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML (ASH 2023) - Nov 3, 2023 - Abstract #4295; Pres time: Dec 11, 2023; 06:00 PM - 08:00 PM; Location: Halls G-H (San Diego Convention Center); "LT based therapy in CBF-GLIS AML provides clinical and laboratory responses that are highly unusual in this refractory patient population. LT has an acceptable safety profile and does not require inpatient delivery. Importantly, LT appears to be enabling these children to receive potential definitive therapy."
Acute Myelogenous Leukemia • Anemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Pediatrics • Respiratory Diseases • CBFA2T3 • FOLR1 • GLIS2
|
|
Robin Williams, MD, MS1; Lane Miller, MD, MSc2; Stephanie Massaro, MD, MPH3; Elizabeth Krieger, MD4; Melinda Pauly, MD5; Catherine Nelson, DO, MS6; Rebecca Johnson, MD7; Jennifer J.G. Welch, MD8; Deepa Bhojwani, MD9; Babak Moghimi, MD10; Philip Neff, MD11; Terzah M. Horton, MD, PhD12; Hamayun Imran, MBBS, MD13; Raul C. Ribeiro, MD14; Terri L. Guinipero, MD15; Matthew A. Kutny, MD16; Felipe Bautista, MD17; Amy Johnson, MD18; Karen Lewing, MD19; Alan S Gamis, MD, MPH20; Julienne Brackett, MD, MS12; David McCall, MD21; Teena Bhatla, MD22; Maria Luisa Sulis, MD23; Amy Tellinghuisen, MD24; Jill C. Beck, MD25; Soheil Meshinchi, MD, PhD26
|